{"groups":[{"description":"Ovarian function suppression (OFS) by triptorelin (GnRH analogue) 3.75mg by im injection q28 days for 5 years plus tamoxifen 20mg orally daily for 5 years. Tamoxifen (T) begins after the completion of adjuvant chemotherapy if given, or approximately 6-8 weeks after the initiation of triptorelin. Bilateral oophorectomy or ovarian irradiation was allowed after at least 6 months of triptorelin.","id":"FG000","title":"T+OFS"},{"description":"Ovarian function suppression (OFS) by triptorelin (GnRH analogue) 3.75mg by im injection q28 days for 5 years plus exemestane 25mg orally daily for 5 years. Exemestane (E) begins after the completion of adjuvant chemotherapy if given, or approximately 6-8 weeks after the initiation of triptorelin. Bilateral oophorectomy or ovarian irradiation was allowed after at least 6 months of triptorelin.","id":"FG001","title":"E+OFS"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"83"},{"groupId":"FG001","numSubjects":"116"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"126"},{"groupId":"FG001","numSubjects":"78"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"45"},{"groupId":"FG001","numSubjects":"43"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"43"},{"groupId":"FG001","numSubjects":"75"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"1334"},{"groupId":"FG001","numSubjects":"1338"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"1034"},{"groupId":"FG001","numSubjects":"1026"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"300"},{"groupId":"FG001","numSubjects":"312"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"2672 patients were randomized between 7Nov03 and 7Apr11 at 182 centers in 15 countries."}